RecruitingPhase 1

AD-SVF Therapy for Refractory Endometrial Infertility

China10 participantsStarted 2025-11

Plain-language summary

The purpose of this study is to initially explore the efficacy of adipose-derived stromal vascular fraction (AD-SVF) therapy in the treatment of refractory endometrial infertility.

Who can participate

Age range22 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. refractory thin endometrium (endometrial thickness \< 6 mm on the day of ovulation or the day of endometrial transformation during a hormone replacement cycle) and/or moderate to severe intrauterine adhesion；
✓. Inability to undergo autologous bone marrow stem cells-scaffold (BMSC) transplantation due to failed bone marrow aspiration, or lack of significant effect following the BMSC treatment;
✓. with fertility intentions;
✓. normal ovarian function or availability of cryopreserved embryos;
✓. 18kg/m\^2 \< body mass index (BMI) \< 30kg/m\^2;

Exclusion criteria

✕. Chromosomal karyotype abnormalities in one spouse;
✕. Severe endometriosis, uterine fibroids affecting the uterine cavity morphology, or uterine malformations;
✕. Abnormalities in coagulation function, hepatic or renal function, or other underlying conditions deemed by the investigator to potentially impact the study's progression (uncontrolled hypertension, diabetes, autoimmune diseases, etc.);
✕. Contraindications for pregnancy;
✕. Contraindications for hormonal cycle therapy;
✕. History of pelvic tumors;
✕. Simultaneous participation in other clinical studies.

What they're measuring

Proportion of patients with endometrial thickness of 6 mm or greater

Timeframe: 6 months after AD-SVF intrauterine infusion therapy

Trial details

NCT IDNCT07230600

SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Yali Hu

86-025-83106666 glyyhuyali@163.com

View on ClinicalTrials.gov More Endometrium; Atrophy trials